Imaging agent developer ImaginAb has signed a collaboration agreement with pharmaceutical companies AstraZeneca, Pfizer, and Takeda Pharmaceutical to further the clinical development of its CD8 PET technology.
The three firms will help guide a current clinical trial that's evaluating the utility and value of CD8 ImmunoPET in immuno-oncology drug development, according to ImaginAb. In exchange, they will receive early access to clinical and imaging data and be able to contribute to the post-trial data analysis, ImaginAb said.
